World J Surg Surg Res | Volume 5, Issue 1 | Research Article | Open Access

Fondaparinux to Prevent Venous Thromboembolism after Bariatric Surgery: An Observational Clinical Trial

Gaspard Bouteloup1, Abdessalem Ghedira1, Mohamed Ali Chaouch1, Adrien Faul1, Carlotta Ferretti1, Sofia Usai1, Zeina Farah1, Clara Cesari1, Marc Beaussier2, Marie-Christine Boutron- Ruault1,3 and Guillaume Pourcher1,3*

1Department of Digestive, Oncologic and Metabolic Surgery, Obesity Center, Institute Mutualiste Montsouris, Paris, France 2Department of Anesthesiology, Institute Mutualiste Montsouris, Paris, France 3Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM, Paris-Saclay University, France

*Correspondance to: Guillaume Pourcher 

Fulltext PDF


Background: Bariatric surgery is associated with a higher risk of thromboembolism complications and requires longer thromboprophylaxis. After hospital discharge, we could use Fondaparinux. This study aimed to assess the effectiveness of Fondaparinux use for postoperative thromboprophylaxis after bariatric surgery. Methods: This prospectively collected data study of consecutive patients undergoing bariatric surgery given Enoxaparin for prophylaxis (40 mg single dose immediately after surgery) followed by Fondaparinux after hospital discharge (2.5 mg to 5 mg for 10 days to 15 days). The outcomes measures were evaluated by questioning, computed tomography, postoperative thromboembolic, and bleeding. The follow-up was of 12 months. Results: One hundred fifty-four patients were enrolled. Eighty-five patients were discharged on the day of surgery and 86 patients on the following day. Before discharge (during Enoxaparin thromboprophylaxis), one patient was identified with asymptomatic pulmonary embolism, one with a major bleeding event, and seven with minor bleeds. One hundred thirty-eight patients (89.6%) were evaluable at 12 months. After discharge, there is no thromboembolic or bleeding events. None of the patients died during the follow-up. Conclusion: Fondaparinux appears safe when used for postoperative thromboprophylaxis following bariatric surgery.


Fondaparinux; Enoxaparin; Venous thromboembolism; Thromboprophylaxis; Bariatric surgery; Laparoscopy; Bleeding


Bouteloup G, Ghedira A, Ali Chaouch M, Faul A, Ferretti C, Usai S, et al. Fondaparinux to Prevent Venous Thromboembolism after Bariatric Surgery: An Observational Clinical Trial. World J Surg Surgical Res. 2022;5:1377..

Subscribe to Our Newsletter